We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Walgreens Boots Alliance (WBA - Free Report) closed the most recent trading day at $72.11, moving -0.44% from the previous trading session. This move lagged the S&P 500's daily loss of 0.27%. Elsewhere, the Dow lost 0.41%, while the tech-heavy Nasdaq added 0.09%.
Coming into today, shares of the largest U.S. drugstore chain had gained 0.6% in the past month. In that same time, the Retail-Wholesale sector gained 4.47%, while the S&P 500 gained 6.26%.
WBA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.74, up 0.58% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $34.72 billion, up 5.16% from the year-ago period.
WBA's full-year Zacks Consensus Estimates are calling for earnings of $6.52 per share and revenue of $136.85 billion. These results would represent year-over-year changes of +8.31% and +4.04%, respectively.
Investors should also note any recent changes to analyst estimates for WBA. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. WBA is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, WBA currently has a Forward P/E ratio of 11.1. Its industry sports an average Forward P/E of 11.1, so we one might conclude that WBA is trading at a no noticeable deviation comparatively.
Meanwhile, WBA's PEG ratio is currently 1.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Retail - Pharmacies and Drug Stores stocks are, on average, holding a PEG ratio of 1.03 based on yesterday's closing prices.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
Walgreens Boots Alliance (WBA - Free Report) closed the most recent trading day at $72.11, moving -0.44% from the previous trading session. This move lagged the S&P 500's daily loss of 0.27%. Elsewhere, the Dow lost 0.41%, while the tech-heavy Nasdaq added 0.09%.
Coming into today, shares of the largest U.S. drugstore chain had gained 0.6% in the past month. In that same time, the Retail-Wholesale sector gained 4.47%, while the S&P 500 gained 6.26%.
WBA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.74, up 0.58% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $34.72 billion, up 5.16% from the year-ago period.
WBA's full-year Zacks Consensus Estimates are calling for earnings of $6.52 per share and revenue of $136.85 billion. These results would represent year-over-year changes of +8.31% and +4.04%, respectively.
Investors should also note any recent changes to analyst estimates for WBA. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. WBA is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, WBA currently has a Forward P/E ratio of 11.1. Its industry sports an average Forward P/E of 11.1, so we one might conclude that WBA is trading at a no noticeable deviation comparatively.
Meanwhile, WBA's PEG ratio is currently 1.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Retail - Pharmacies and Drug Stores stocks are, on average, holding a PEG ratio of 1.03 based on yesterday's closing prices.
The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.